Monday, August 22, 2011
Cytokinetics Inc., of South San Francisco, said The Lancet published results from two studies supporting the use of omecamtiv mecarbil in heart failure.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.